Home/Poxel/David S. Horn

DS

David S. Horn

Chief Medical Officer

Therapeutic Areas

Non-alcoholic Steatohepatitis (NASH)Rare Metabolic Disorders Type 2 Diabetes

Poxel Pipeline

Drug	Indication	Phase
PXL065	Non-alcoholic steatohepatitis (NASH)	Phase 2
PXL770	Rare Metabolic Diseases (e.g., ADPKD)	Phase 2a
TWYMEEG (Imeglimin)	Type 2 Diabetes	Marketed

Leadership Team at Poxel

Chief Executive Officer

Sébastien Bolze

Founder and Chairman of the Board

Cécile Baudrier

Chief Financial Officer

View full Poxel profile